A Multi-Center, Randomized, Double-Blind, Placebo- Controlled Clinical Trial of the Safety and Efficacy of Convalescent Plasma for the Treatment of COVID-19 in Hospitalized Patients in Lagos State

Abayomi et al., PACTR202006760881890, LACCPT, PACTR202006760881890

Nov 2021

Source PDF All Studies Meta AnalysisMeta

RCT 22 hospitalized patients, show no significant difference in mortality with convalescent plasma. Results are from Axfors et al..

Important missing comments or errors? Let us know.

risk of death, 16.7% higher, RR 1.17, p = 1.00, treatment 7 of 11 (63.6%), control 6 of 11 (54.5%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. Axfors et al., Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials, BMC Infectious Diseases, doi:10.1186/s12879-021-06829-7.biomedcentral.com, doi.org.

Abayomi et al., 20 Nov 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Nigeria, peer-reviewed, 1 author, trial PACTR202006760881890 (LACCPT).

This Paper Conv. Plasma All

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0